<DOC>
	<DOCNO>NCT01764594</DOCNO>
	<brief_summary>To evaluate safety , tolerability pharmacokinetics immunogenicity CDP7657 .</brief_summary>
	<brief_title>Safety Study CDP7657 Patients With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Patients Systemic Lupus Erythematosus ( SLE ) Severe neuropsychiatric severe renal Systemic Lupus Erythematosus ( SLE ) History chronic , recurrent , recent severe infection Significant hematologic abnormality History cancer , heart failure , renal disease , liver disease serious illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
</DOC>